✦ LIBER ✦

A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma

✍ Scribed by Edith A. Perez; David W. Hillman; Philip J. Stella; James E. Krook; Lynn C. Hartmann; Tom R. Fitch; Alan K. Hatfield; James A. Mailliard; Suresh Nair; Carl G. Kardinal; James N. Ingle

Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 96 KB
Volume: 88
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(20000101)88:1<124::aid-cncr17>3.0.co;2-f

No coin nor oath required. For personal study only.

✦ Synopsis

BACKGROUND.

This Phase II multicenter study evaluated the efficacy and toxicity of paclitaxel (200 mg/m 2 by 3-hour infusion) with carboplatin (area under the curve 6 mg/mL per minute) administered every 3 weeks as first-line therapy for women with metastatic breast carcinoma.

METHODS. Eligible patients had measurable metastatic disease and an Eastern

Cooperative Oncology Group performance status of 0 -2. Prior adjuvant chemotherapy, including anthracycline-based therapy, was allowed, as was prior hormonal therapy as part of either adjuvant treatment or treatment for metastasis.

Prior therapy with taxanes or platinum was not allowed.

📜 SIMILAR VOLUMES

Phase II study of paclitaxel in patients

Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy

✍ Edgardo Rivera; Frankie A. Holmes; Debra Frye; Vicente Valero; Richard L. Theria 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

Phase II study of irinotecan as first-li

Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma

✍ José Luis Fírvida; Antonio Irigoyen; Sergio Vázquez-Estévez; Pilar Díz; Manuel C 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

Phase II study of paclitaxel and epirubi

Phase II study of paclitaxel and epirubicin as first-line treatment in patients with metastatic nonsmall cell lung carcinoma

✍ Giovanni L. Ceresoli; Stefania Dell'Oro; Paolo Passoni; Eugenio Villa 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

A randomized Phase II trial of two dosag

A randomized Phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma

✍ James N. Ingle; Patricia A. Johnson; Vera J. Suman; James B. Gerstner; James A. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 2 views

letrozole dosage levels, 0.5 mg and 2.5 mg per day, was performed. Eligibility requirements included failure on two prior hormonal therapies and measurable

Paclitaxel-based second-line therapy for

Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1) : A clinical Phase II study

✍ Thomas Otto; Axel Bex; Susanne Krege; Peter H. Walz; Herbert Rübben 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 2 views

and an antimotility factor (acellular pertussis vaccine [APV]) in 18 School, Essen, Germany. patients with cisplatin-and methotrexate-resistant metastatic bladder carcinoma. Intramuscular injection of APV 3 times in the first week, on Days 1, 4, and 7, was

Paclitaxel, cisplatin, and epirubicin fi

Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in Stage III and IV ovarian carcinoma : Long term results of a Phase II study

✍ Christos A. Papadimitriou; Lia A. Moulopoulos; Georgios Vlahos; Zannis Voulgaris 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 1 views

## Background: The combination of paclitaxel with cisplatin or carboplatin has become the preferred chemotherapy regimen in the treatment of epithelial ovarian carcinoma. anthracyclines also have activity in this disease. we conducted a phase ii study by using the combination of paclitaxel, cisplat